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Fluoroquinolones compared to 1% azithromycin in DuraSite® 
for bacterial conjunctivitis
In a recent issue of Clinical Ophthalmology, Friedlaender and Protzko (2007) review the 
development and efﬁ  cacy of 1% azithromycin in DuraSite® (AzaSite™, Inspire Phar-
maceuticals, Inc., Durham, NC) for the treatment of bacterial conjunctivitis. The authors 
conclude that 1% azithromycin in DuraSite offers a simpliﬁ  ed dosing regimen with sus-
tained bactericidal levels that decrease resistance development. While 1% azithromycin in 
DuraSite is a new formulation of azithromycin that allows topical ocular use, azithromycin 
and DuraSite have been around for many years. Evidence demonstrates a greater potential 
for emerging resistance with azithromycin, an older drug, especially when formulated in 
a vehicle that prolongs low levels of antibiotic exposure over time.
Azithromycin is derived from the parent class of macrolides, known to be bac-
teriostatic. The ability of azithromycin to achieve high intracellular concentrations 
compared with other macrolides is credited for its bactericidal activity. However, in 
clinical practice, given the high level of Gram-positive resistance patterns, azithromycin 
demonstrates time-dependent, bacteriostatic kill against most bacteria within its clinical 
spectrum. DuraSite technology allows azithromycin to stay in contact with the ocular 
surface longer than conventional aqueous eye drops; a potential concern for resistance 
that led to a US Food and Drug Administration (FDA) warning on their package insert 
regarding missing doses: “Skipping doses or not completing the full course of therapy 
may … increase the likelihood that bacteria will develop resistance and will not be 
treatable by AzaSite (azithromycin ophthalmic solution) or other antibiotic drugs in 
the future.” (Azasite 2007). In contrast, potent, rapid-killing, broad-spectrum topical 
anti-infectives are less likely to promote resistance and do not carry such an FDA 
warning. Among these agents are the ophthalmic fourth-generation ﬂ  uoroquinolones 
(FQs) that demonstrate concentration-dependent bactericidal kill and are not reliant 
on time as suggested by the authors.
The authors state that changing trends in the activity of newer-generation FQs dem-
onstrate increased resistance among common bacterial conjunctivitis pathogens such 
as Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus inﬂ  uenzae. 
However, within the article, all 3 cited references (Goldstein et al 1999; Venezia et al 
2001; Ambrose et al 2004) document resistance patterns in older-generation FQs 
instead of newer fourth-generation agents such as moxiﬂ  oxacin 0.5% and gatiﬂ  oxacin 
0.3%. The distinction is critical. The development of resistance to older FQs develops 
through a single-step topoisomerase mutation (topoisomerase II or topoisomerase 
IV). However, resistance to newer FQs requires 2 spontaneous mutations at both 
topoisomerase II and topoisomerase IV and occurs much less frequently (Hwang 2004). 
In fact, in isolates of S. aureus, S. pneumoniae, and H. inﬂ  uenzae from conjunctivitis 
patients seen in a community practice setting, resistance to a fourth-generation agent, 
moxiﬂ  oxacin, was not observed (Ohnsman et al 2007).
This study showed that only when combined with extra vehicle drops (likely 
containing preservative) for a total of 4 applications per day could 1% azithromycin 
in DuraSite (dosed twice daily for the ﬁ  rst 2 days, then daily for 3 days) achieve a 
success proﬁ  le similar to tobramycin dosed four times daily for 5 days. Since the 
clinical resolution rate of 1% azithromycin in DuraSite dosed in combination with Clinical Ophthalmology 2008:2(1) 242
Lichtenstein and Granet
13 drops of vehicle (total of 20 drops) in the comparative 
tobramycin study was higher (79.9%) than reported in 
the comparative vehicle study (63.1%) with only 7 drops 
of azithromycin, it is probable that the numerous extra 
drops of vehicle created a washout effect or provided 
some antibacterial activity. In fact, given that the 2 arms 
of the study were performed simultaneously, the data 
indicate that without the 13 extra washout drops of vehicle, 
azithromycin would not have even reached equivalence to 
tobramycin.
Furthermore, a numerical advantage and statistical trend 
toward greater bacterial eradication with 0.3% tobramy-
cin (94.3%) compared with 1% azithromycin in DuraSite 
(88.1%) (p = 0.073) was observed, although there was no 
overall difference in the rate of clinical resolution at the test-
of-cure visit on Day 6 between agents; a ﬁ  nding we suggest 
may be related to the self-limiting nature of the disease. High 
failure rates of bacterial eradication (ie, resistant isolates of S. 
aureus and S. pneumoniae 50% and 40%, respectively) were 
observed as were lower rates of overall clinical resolution 
(70.6% and 85.5%, respectively) in all patients infected with 
azithromycin-resistant isolates.
Clinicians should consider the speed in which a therapy 
eradicates infection, the anticipated spectrum of activity, 
tolerability, compliance, and cost of therapy when choos-
ing empiric antibiotic therapy. While 1% azithromycin in 
DuraSite offers the perceived advantage of fewer doses, 
equivalence to tobramycin was only reached by adminis-
tering 1 drop of 1% azithromycin in DuraSite with 3 drops 
of vehicle (ie, 4 drops) in the eye each day, questioning 
the overall efﬁ  cacy of a true once-daily regimen. Also 
disconcerting is this agent’s potential to select for resistant 
pathogens that can be transmitted to the fellow eye of the 
patient or to other close contacts as warned by the FDA 
in the package insert. Furthermore, less frequent dosing 
does not always translate into increased compliance. If a 
therapy is not tolerable, the beneﬁ  t of less frequent dosing 
may not be realized. In a recently completed study, the 
fourth-generation FQ, moxiﬂ  oxacin 0.5%, was found to 
be more comfortable, resulted in less blurring, and was 
preferred (84% to 16%) over 1% azithromycin in DuraSite 
(Granet et al 2007).
After reviewing the data from the authors presented 
in their article we must disagree that 1% azithromycin in 
DuraSite “appears more favorable than the currently avail-
able choices in the UK and US.” When clinicians consider all 
factors related to therapy (eg, bacterial resistance, blurriness, 
dosing compliance, and comfort) we suggest rapid-killing 
bactericidal agents such as ophthalmic fourth-generation 
ﬂ  uoroquinolones are better options for the treatment of 
conjunctivitis.
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In our review of the development and efﬁ  cacy of 1% azithro-
mycin in DuraSite® (AzaSite™, InSite Vision, Alameda, CA, 
USA) published in Clinical Ophthalmology (Friedlaender 
and Protzko 2007), we describe azithromycin as a well 
known anti-infective agent with pharmacokinetic proper-
ties that were not sufﬁ  ciently exploited for topical use in the 
eye until the development of AzaSite. A sustained release 
ocular antibiotic, AzaSite delivers sufﬁ  ciently high con-
centrations of azithromycin to the eye to eradicate common 
causative pathogens of bacterial conjunctivitis. The means 
by which azithromycin is delivered to the eye in the AzaSite 
formulation gives it much greater tissue concentrations than 
expected.Clinical Ophthalmology 2008:2(1) 243
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The DuraSite vehicle completely solubilizes azithromy-
cin in a matrix that stays in contact with the ocular surface 
longer than conventional aqueous drops. A full course of 
therapy of AzaSite for bacterial conjunctivitis requires only 
9 drops. Drs Lichtenstein and Granet (2007) suggest that this 
is a potential concern for the development of drug resistance 
and it is also the reason why the US Food and Drug Admin-
istration (FDA) places a warning about skipping doses on 
the package insert.
We would like to point out that, regardless of the anti-
infective used, the misuse of an antibiotic – including failure 
to complete therapy, skipping doses, or reuse of leftover 
antibiotic – may expose patients to the development of bacte-
rial resistance. Warnings of this nature appear on the patient 
information inserts for a variety of antibiotics, including 
Avelox® (oral moxiﬂ  oxacin). The guidance in the patient 
counseling section of AzaSite’s prescribing information is 
reﬂ  ective of the FDA’s acknowledgement of widespread 
antibiotic misuse and new requirements for labeling.
Aside from these matters of newer packaging guide-
lines, the potential for the development of resistance with 
topical 1% azithromycin in DuraSite is minimized by its 
newer delivery method and by azithromycin’s afﬁ  nity for 
tissue, resulting in high concentrations of drug in tears and 
conjunctiva. During the pivotal trials for 1% azithromycin 
in DuraSite, no indication of the development of resistance 
to azithromycin was observed. MICs of cultured bacteria did 
not increase during treatment with AzaSite. Furthermore, in 
the vehicle trial, AzaSite effectively eradicated 85% (23/27) 
of azithromycin-resistant pathogens.
Pivotal trials for AzaSite were conducted in patients 
with bacterial conjunctivitis, which commonly presents as 
a self-limited disease but may be severe in some cases. The 
value of drug intervention to eradicate bacteria and speed 
resolution of the signs and symptoms must be measured at 
an early phase in the disease process in order to assess the 
efﬁ  cacy of treatment. We reject the suggestion that the high 
rate of clinical cure measured at day 6 in the AzaSite pivotal 
trial was related to the self-limited nature of the disease.
In support of this, we point out that a comparison 
of clinical cure (resolution of all signs and symptoms) 
achieved with moxiﬂ  oxacin and azithromycin yields highly 
similar results at the end of a 5-day dosing period – and 
in both cases the rates are signiﬁ  cantly better than with 
vehicle – refuting the notion that by day 6 clinical cure 
rates would have improved without intervention. AzaSite 
attained the same level of clinical cure as moxiﬂ  oxacin 
with 50% fewer active drops. Patients in the phase 3 trials 
for moxiﬂ  oxacin were dosed three times a day for 4 days. 
Compared to vehicle, the difference in the rate of clinical 
cure was signiﬁ  cant at day 5 but not at the test-of-cure 
on day 9, when according to most clinical accounts the 
symptoms had begun to resolve on their own (Table 1). The 
rate of bacterial eradication (82%) was measured at day 9 
in the moxiﬂ  oxacin group, compared to 89% on Day 6 + 1 
in the AzaSite trial.
Lack of susceptibility to fourth-generation ﬂ  uoroqui-
nolones in vitro was reported in the AzaSite clinical trials. 
Although the number of instances was small, more than 50% 
of these ﬂ  uoroquinolone-resistant isolates were susceptible to 
AzaSite. Recent clinical and epidemiologic studies have also 
reported resistance to the new fourth-generation ﬂ  uoroqui-
nolones, including moxiﬂ  oxacin. In addition to the ﬁ  ndings 
in the AzaSite clinical trials, reports of 4th generation ﬂ  uro-
quinolone resistant bacteria have been growing in number as 
reported in bacterial keratitis and following cataract surgery, 
and refractive surgery (Jhanji et al 2007; Mamalis 2007; Melo 
et al 2007; Ta and Sahm 2007).
Smart use of the appropriate antibiotic is the key to 
controlling the spread of resistance (CDC 2006). Fourth 
generation ﬂ  uoroquinolones are powerful drugs, but declin-
ing in vitro susceptibility as measured over the past 5 years 
has important implications for their use in relatively mild 
infections such as uncomplicated conjunctivitis or chronic 
infections such as blepharitis (Miller et al 2006; Mamalis 
2007). A systematic meta-analysis of antibiotic misuse by 
Kardas and colleagues (2005) concludes that patient educa-
tion and simpler antibiotic regimens should be encouraged to 
promote responsible use of antibiotic therapy. Most antibacte-
rial eye drops currently available require 3 to 8 doses daily 
for 7 to 10 days, a demanding dosing schedule that can result 
in missed doses and unﬁ  nished courses of therapy (Kernt 
Table 1 Clinical cure of bacterial conjunctivitis in 0.5% 
moxiﬂ  oxacin vs. vehicle in phase 3 clinical trial (FDA 2003)*
  Cumulative  % Clinical cure    p value
 Drops;  No.  Moxiﬂ  oxacin  Vehicle
Day  3  9 27 15  0.0186
Day 5   15  66  51  0.0096†
(end-of-
therapy)
Day 9   15  83  74  0.0991
(test-of-
cure)
Notes: *Data are from modiﬁ  ed intent-to-treat population and includes all patients 
who met inclusion criteria, received treatment, had at least 1 follow up visit, and were 
culture-positive for bacteria on day 1; †p  0.05.Clinical Ophthalmology 2008:2(1) 244
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et al 2005). AzaSite is recommended for dosing twice daily 
on the ﬁ  rst two days of treatment, followed by once-daily 
dosing on days 3 through 7. In interviews of 141 patients, 
Kass and colleagues (1982) concluded that simplifying 
patient instruction and dosing schedules for eye drops would 
improve compliance. With twice-daily dosing for the ﬁ  rst two 
days and simple once-daily dosing for the remainder of the 
treatment period, AzaSite simpliﬁ  es the regimen normally 
associated with antibiotic eye drops.
A patient’s level of adherence to an appropriate anti-
infective treatment regimen is a key variable in curing acute 
bacterial infections. Adherance can be difﬁ  cult for some 
patients to maintain and even more difﬁ  cult for healthcare 
providers to measure (Schwartz et al 2004). This was dem-
onstrated in the comparative tolerability study by Dr. Granet 
and colleagues (2007). Their study comparing assessments 
of Vigamox and AzaSite in healthy patients was not fully 
masked, and highly dependent on subjective descriptions of 
tolerability. The introduction of investigator bias in this type 
of study cannot by ruled out.
Most potent eye drops are associated with some 
transient sensations when they are ﬁ  rst instilled and it is 
incorrect to label these sensations as “adverse events”. 
Loss of vision, glaucoma, and allergic reactions would 
be considered “adverse events” by most standards. The 
symptoms categorized as “adverse events” by Granet and 
colleagues (2007), would not. In two much larger stud-
ies, which were double-masked, we described transient 
symptoms, such as burning, stinging, and itching which 
were not statistically different in the AzaSite and vehicle 
groups. Furthermore, these were double-masked studies 
in inﬂ  amed red eyes which should have been highly sensi-
tive to irritants.
Once-daily dosing of eye drops has been associated with 
enhanced patient compliance, which minimizes the potential 
for the development of resistant organisms. As a result, short 
and convenient means of treating ocular infection is essential 
to improve compliance, outcome, and minimize the potential 
for the development of resistance.
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